Status: Recruiting
Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer
This study primarily aims to assess the safety and tolerability of XP-004 personalized mRNA vaccines encoding tumor neoantigens combined with PD-1 inhibitor as adjuvant therapy for chemotherapy-intolerant patients following radical pancreatic cancer resection. Secondary objectives focus on evaluating preliminary efficacy through three parameters: 1) XP-004-induced antigen-specific CD4+/CD8+ T cell activation levels, 2) recurrence-free survival (RFS), and 3) overall survival (OS) in post-operative pancreatic cancer patients receiving this combination therapy.
Participants needed: 20
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Ruijin HospitalUpdated: Nov 17, 2025Locations: 1
Eligibility criteria
Subjects voluntarily signed written informed consent files,Able to comply with t... [+5]
Has had chemotherapy, traditional Chinese medicine with antitumor indications, o... [+3]